Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
OBJECTIVE
Cytochrome P450 2C9 and 2C19 (CYP2C9 and CYP2C19, respectively) genetic polymorphisms play an important role in phenytoin (PHT) metabolism. We have evaluated whether these genetic polymorphisms have an effect on PHT-induced neurological toxicity in Tamilian (ethnic group native to southern India) patients with epilepsy.


METHODS
We studied 292 Tamilian patients who were taking PHT for the treatment of various epileptic seizures. PHT toxicity was defined on the basis of neurological signs of toxicity and further sub-classified into mild, moderate, and severe toxicity based on clinical severity. Genomic DNA was extracted from peripheral leukocytes and genotyped for CYP2C9*2, *3 and CYP2C19*2, *3 by PCR-restriction fragment length polymorphism analysis.


RESULTS
Of the 292 patients in the patient cohort, 58 were clinically diagnosed to have PHT toxicity. When risk ratios were calculated for each mutant CYP2C9 genotype separately, the adjusted odds ratio for CYP2C9*1/*3 was found to be 15.3 (95% confidence interval 5.8-40.3, P<0.0001) for the cases compared to controls. When the four single nucleotide polymorphisms of CYP2C9 and CYP2C19 were analyzed using a haplotype approach, significant difference in the distribution of the C-C-G-G haplotype was observed between the cases and controls.


CONCLUSIONS
Our results show that CYP2C9 genetic polymorphisms (particularly the *3 allele) were associated with high risk of epileptic patients developing PHT-induced neurological toxicity.
Kesavan
Ramasamy
R
Department of Pharmacology, Center for Advance Research in Pharmacogenomics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605006, India.
Narayan
Sunil K
SK
Adithan
Chandrasekaran
C
D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D065729:Cytochrome P-450 CYP2C9; D004827:Epilepsy / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D006239:Haplotypes; D006801:Humans; D007194:India; D008297:Male; D020258:Neurotoxicity Syndromes / Q000235:genetics*; D010672:Phenytoin / Q000009:adverse effects* / Q000493:pharmacokinetics*; D020641:Polymorphism, Single Nucleotide
D010672:Phenytoin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19
Clin Chem. 1984 Jan;30(1):105-8
6690110
Nature. 2009 Sep 24;461(7263):489-94
19779445
Drug Metab Dispos. 1996 Dec;24(12):1401-3
8971149
Br J Clin Pharmacol. 2003 Sep;56(3):331-3
12919183
Mol Pharmacol. 1994 Oct;46(4):594-8
7969038
Eur J Clin Pharmacol. 2003 Nov;59(8-9):707-9
14504850
Neurocrit Care. 2009;10(2):222-4
19030785
Fundam Clin Pharmacol. 2005 Feb;19(1):101-5
15660966
Clin Pharmacol Ther. 1997 Sep;62(3):287-92
9333104
Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7
271968
Br J Clin Pharmacol. 1999 Sep;48(3):409-15
10510154
Br J Clin Pharmacol. 2005 Oct;60(4):418-22
16187974
Epilepsia. 1975 Dec;16(5):753-8
1222751
J Assoc Physicians India. 2008 Apr;56:250-2
18702389
Fundam Clin Pharmacol. 2003 Jun;17(3):373-6
12803577
Pharmacogenetics. 1996 Aug;6(4):341-9
8873220
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1257-70
12406644
J Biol Chem. 1994 Jun 3;269(22):15419-22
8195181
Neurology. 2003 Apr 22;60(8):1395-6
12707459
Pharmacol Res. 2004 Aug;50(2):195-200
15177309
Thromb Haemost. 2002 Nov;88(5):874-5
12428110
Indian J Med Res. 2006 May;123(5):665-70
16873909
Curr Clin Pharmacol. 2007 Jan;2(1):93-109
18690857
Pharmacogenetics. 1994 Feb;4(1):39-42
8004131
J Clin Pharm Ther. 2006 Jun;31(3):275-82
16789993
Eur J Clin Pharmacol. 2004 May;60(3):155-9
15024534
Pharmacogenomics J. 2001;1(3):204-10
11908757
Ther Drug Monit. 1998 Jun;20(3):243-7
9631918
N Z Med J. 2008 Apr 18;121(1272):33-7
18425152
J Clin Pharmacol. 2009 Dec;49(12):1483-7
19617466
Pharmacogenetics. 2000 Mar;10(2):95-104
10761997
Biol Pharm Bull. 1996 Aug;19(8):1103-5
8874828
Br J Clin Pharmacol. 2001 Oct;52(4):447-50
11678789
Clin Neuropharmacol. 1998 Mar-Apr;21(2):122-6
9579299
Neurol India. 2007 Oct-Dec;55(4):408-9
18040121
Ther Drug Monit. 2000 Apr;22(2):230-2
10774639
Pharmacogenetics. 2001 Dec;11(9):803-8
11740344
Epilepsia. 1998 Dec;39(12):1317-23
9860067
Epilepsy Res. 1999 Jul;35(3):253-5
10413320
Arch Neurol. 1964 Dec;11:642-8
14202181